The aim of this study is to describe, in a real-life context, the impact of an epoetin alpha biosimilar, Retacrit®, on anaemia in patients receiving chemotherapy, according to concomitant iron supplementation.

This is a longitudinal, observational, prospective, multicentre, cohort study, conducted on a representative sample of public and/or private hospital-based oncologists and haematologists practicing in Metropolitan France.

Inclusion Criteria:

• Adult patients, aged 18 years and older, seen by the oncologist or hematologist for chemotherapy.
• Patients for whom the oncologist or hematologist has decided the initiation of an epoetin alpha biosimilar treatment (Retacrit®) for anemia.
• Patients informed about the computer processing of their medical data and their right of access and correction.

Exclusion Criteria:

• Patients with hemoglobin concentrations >11 g/dL.
• Patients who have been transfused within the previous month.
• Patients who are hypersensitive to erythropoietin or one of its excipients.
• Patients participating or having participated in the previous month in a clinical trial in the field of anaemia in oncology.
• Patients refusing to participate in the observational study.

Patients for whom the oncologist decides to initiate epoetin alpha biosimilar treatment (curative or prophylactic) will be asked to participate from treatment initiation (baseline visit) up to 12-16 weeks after inclusion.